List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2298809/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Synergy between glutamate modulation and anti–programmed cell death protein 1 immunotherapy for glioblastoma. Journal of Neurosurgery, 2022, 136, 379-388.	1.6	11
2	Combined intracranial Acriflavine, temozolomide and radiation extends survival in a rat glioma model. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 170, 179-186.	4.3	2
3	Translational Regulation by hnRNP H/F Is Essential for the Proliferation and Survival of Glioblastoma. Cancers, 2022, 14, 1283.	3.7	3
4	Crossing the Blood-Brain Barrier: Advances in Nanoparticle Technology for Drug Delivery in Neuro-Oncology. International Journal of Molecular Sciences, 2022, 23, 4153.	4.1	74
5	Metformin and Cancer, an Ambiguanidous Relationship. Pharmaceuticals, 2022, 15, 626.	3.8	22
6	Ultrasound monitoring of microcirculation: An original study from the laboratory bench to the clinic. Microcirculation, 2022, 29, .	1.8	9
7	Buprenorphine implants: a model for expedited development and approval of new drugs. Current Medical Research and Opinion, 2021, 37, 83-88.	1.9	1
8	CDKS Blockade Enhances In Vivo Efficacy of EGFR Inhibition in Chordomas. Journal of Neurological Surgery, Part B: Skull Base, 2021, 82, .	0.8	0
9	Preclinical efficacy of ribavirin in SHH and group 3 medulloblastoma. Journal of Neurosurgery: Pediatrics, 2021, 27, 482-488.	1.3	7
10	Pectic Galactan Polysaccharideâ€Based Gene Delivery System for Targeting Neuroinflammation. Advanced Functional Materials, 2021, 31, 2100643.	14.9	4
11	Pharmacological strategies for improving the prognosis of glioblastoma. Expert Opinion on Pharmacotherapy, 2021, 22, 2019-2031.	1.8	8
12	High-Intensity Focused Ultrasound: A Review of Mechanisms and Clinical Applications. Annals of Biomedical Engineering, 2021, 49, 1975-1991.	2.5	77
13	Captopril inhibits Matrix Metalloproteinase-2 and extends survival as a temozolomide adjuvant in an intracranial gliosarcoma model. Clinical Neurology and Neurosurgery, 2021, 207, 106771.	1.4	6
14	Neurosurgical Implant-Based Strategy for Brain Cancer Therapy. Neuromethods, 2021, , 225-244.	0.3	1
15	Disulfiram and copper combination therapy targets NPL4, cancer stem cells and extends survival in a medulloblastoma model. PLoS ONE, 2021, 16, e0251957.	2.5	8
16	Drug Repurposing for Glioblastoma and Current Advances in Drug Delivery—A Comprehensive Review of the Literature. Biomolecules, 2021, 11, 1870.	4.0	13
17	Nonviral polymeric nanoparticles for gene therapy in pediatric CNS malignancies. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 23, 102115.	3.3	35
18	Intraoperative Laser Speckle Contrast Imaging For Real-Time Visualization of Cerebral Blood Flow in Cerebrovascular Surgery:ÂResults From Pre-Clinical Studies. Scientific Reports, 2020, 10, 7614.	3.3	30

#	Article	IF	CITATIONS
19	Evaluating the Effects of Cerebrospinal Fluid Protein Content on the Performance of Differential Pressure Valves and Antisiphon Devices Using a Novel Benchtop Shunting Model. Neurosurgery, 2020, 87, 1046-1054.	1.1	4
20	Repurposing the FDA-Approved Antiviral Drug Ribavirin as Targeted Therapy for Nasopharyngeal Carcinoma. Molecular Cancer Therapeutics, 2020, 19, 1797-1808.	4.1	9
21	Novel therapeutics for brain tumors: current practice and future prospects. Expert Opinion on Drug Delivery, 2020, 17, 9-21.	5.0	10
22	EXTH-61. COMBINATION OF DISULFIRAM AND COPPER INDUCES NPL4 AGGREGATION, TARGETS CD133-NESTIN CELLS AND EXTENDS SURVIVAL IN MEDULLOBLASTOMA GROUP 3 MODELS. Neuro-Oncology, 2020, 22, ii100-ii100.	1.2	0
23	Drug-Impregnated Polymer Delivery. , 2019, , 275-296.		0
24	The Use of Ribavirin as an Anticancer Therapeutic: Will It Go Viral?. Molecular Cancer Therapeutics, 2019, 18, 1185-1194.	4.1	49
25	Evaluation of select biocompatible markers for labelling peripheral nerves on 11.7 T MRI. Journal of Neuroscience Methods, 2019, 315, 6-13.	2.5	0
26	Overall Survival in Malignant Glioma Is Significantly Prolonged by Neurosurgical Delivery of Etoposide and Temozolomide from a Thermo-Responsive Biodegradable Paste. Clinical Cancer Research, 2019, 25, 5094-5106.	7.0	32
27	Multi-layered core-sheath fiber membranes for controlled drug release in the local treatment of brain tumor. Scientific Reports, 2019, 9, 17936.	3.3	38
28	Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer. Journal of Controlled Release, 2019, 295, 93-101.	9.9	64
29	A miniature multi-contrast microscope for functional imaging in freely behaving animals. Nature Communications, 2019, 10, 99.	12.8	62
30	Design considerations for a miniature multicontrast neuroimager. , 2019, , .		0
31	A Long-Term Study of a Lipid-Buprenorphine Implant in Rats. Journal of Veterinary Medicine, 2018, 2018, 1-4.	1.6	2
32	TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. Oncolmmunology, 2018, 7, e1466769.	4.6	217
33	Interstitial Chemotherapy and Polymer Drug Delivery. , 2018, , 155-165.		0
34	Suspected Lonely Mouse Syndrome as a Cage Effect in a Drug Safety Study. Journal of Veterinary Medicine, 2018, 2018, 1-5.	1.6	3
35	Targeted Local Therapy for Management of Intracranial High-Grade Gliomas. Progress in Neurological Surgery, 2018, 32, 159-171.	1.3	5
36	Ribavirin as a potential therapeutic for atypical teratoid/rhabdoid tumors. Oncotarget, 2018, 9, 8054-8067.	1.8	15

#	Article	IF	CITATIONS
37	Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma. Oncotarget, 2018, 9, 20681-20697.	1.8	63
38	Convection enhanced delivery of cisplatin-loaded brain penetrating nanoparticles cures malignant glioma in rats. Journal of Controlled Release, 2017, 263, 112-119.	9.9	90
39	The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma. Journal of Neuro-Oncology, 2017, 135, 47-56.	2.9	10
40	HIF-1α- Targeting Acriflavine Provides Long Term Survival and Radiological Tumor Response in Brain Cancer Therapy. Scientific Reports, 2017, 7, 14978.	3.3	62
41	Subcutaneous Implants of a Cholesterol-Triglyceride-Buprenorphine Suspension in Rats. Journal of Veterinary Medicine, 2017, 2017, 1-11.	1.6	6
42	Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients. Oncotarget, 2017, 8, 80124-80138.	1.8	33
43	Developing Therapies for Brain Tumors: The Impact of the Johns Hopkins Hunterian Neurosurgical Research Laboratory. Transactions of the American Clinical and Climatological Association, 2017, 128, 55-74.	0.5	2
44	IMST-58. MODULATING THE MYELOID COMPARTMENT TO POTENTIATE ANTI-PD1 MEDIATED IMMUNOTHERAPY AGAINST GLIOBLASTOMA. Neuro-Oncology, 2016, 18, vi99-vi99.	1.2	0
45	TMOD-35. PRIMARY AND RECURRENT SACRAL CHORDOMA AFFECTS THE HIND LIMBS MOTOR AND NOCICEPTIVE FUNCTION IN RATS: AN ORTHOTOPIC SPINE MODEL. Neuro-Oncology, 2016, 18, vi214-vi214.	1.2	1
46	Anti–PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. Science Translational Medicine, 2016, 8, 370ra180.	12.4	243
47	The Johns Hopkins Hunterian Laboratory Philosophy: Mentoring Students in a Scientific Neurosurgical Research Laboratory. Academic Medicine, 2016, 91, 778-784.	1.6	10
48	Polylactic acid (PLA) controlled delivery carriers for biomedical applications. Advanced Drug Delivery Reviews, 2016, 107, 163-175.	13.7	725
49	Non-virally engineered human adipose mesenchymal stem cells produce BMP4, target brain tumors, and extend survival. Biomaterials, 2016, 100, 53-66.	11.4	84
50	Synthesis, characterization, and self-assembly with plasmid DNA of a quaternary ammonium derivative of pectic galactan and its fluorescent labeling for bioimaging applications. Carbohydrate Polymers, 2016, 150, 308-318.	10.2	20
51	Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma. , 2016, 4, 28.		52
52	The effect of regadenoson-induced transient disruption of the blood–brain barrier on temozolomide delivery to normal rat brain. Journal of Neuro-Oncology, 2016, 126, 433-439.	2.9	41
53	Nanobiotechnology-based delivery strategies: New frontiers in brain tumor targeted therapies. Journal of Controlled Release, 2016, 240, 443-453.	9.9	47
54	Quantitative correlational study of microbubbleâ€enhanced ultrasound imaging and magnetic resonance imaging of glioma and early response to radiotherapy in a rat model. Medical Physics, 2015, 42, 4762-4772.	3.0	14

#	Article	IF	CITATIONS
55	Inhibition of Corneal Neovascularization by Subconjunctival Injection of Fc-Endostatin, a Novel Inhibitor of Angiogenesis. Journal of Ophthalmology, 2015, 2015, 1-8.	1.3	8
56	Safety studies of post-surgical buprenorphine therapy for mice. Laboratory Animals, 2015, 49, 100-110.	1.0	17
57	Polymeric Nanoparticles for Nonviral Gene Therapy Extend Brain Tumor Survival <i>in Vivo</i> . ACS Nano, 2015, 9, 1236-1249.	14.6	203
58	Interstitial chemotherapy for malignant glioma: Future prospects in the era of multimodal therapy. , 2015, 6, 78.		17
59	Miniaturized optical neuroimaging in unrestrained animals. NeuroImage, 2015, 113, 397-406.	4.2	27
60	Uniform brain tumor distribution and tumor associated macrophage targeting of systemically administered dendrimers. Biomaterials, 2015, 52, 507-516.	11.4	83
61	MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel. Journal of Clinical Neuroscience, 2015, 22, 1938-1942.	1.5	21
62	Local delivery of cancer-cell glycolytic inhibitors in high-grade glioma. Neuro-Oncology, 2015, 17, 70-80.	1.2	42
63	<i>Clostridium novyi</i> -NT can cause regression of orthotopically implanted glioblastomas in rats. Oncotarget, 2015, 6, 5536-5546.	1.8	65
64	Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model. PLoS ONE, 2014, 9, e101764.	2.5	206
65	Current and Future Novel Treatments for Glioblastoma Multiforme. BioMed Research International, 2014, 2014, 1-1.	1.9	1
66	Thermal latency studies in opiate-treated mice. Journal of Pharmacy and Bioallied Sciences, 2014, 6, 43.	0.6	21
67	Subcutaneous implants for long-acting drug therapy in laboratory animals may generate unintended drug reservoirs. Journal of Pharmacy and Bioallied Sciences, 2014, 6, 38.	0.6	8
68	Extravascular Optical Coherence Tomography. Stroke, 2014, 45, 1123-1130.	2.0	9
69	Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models. Journal of Neuro-Oncology, 2014, 116, 59-65.	2.9	24
70	Intracranial microcapsule chemotherapy delivery for the localized treatment of rodent metastatic breast adenocarcinoma in the brain. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16071-16076.	7.1	25
71	Efficacy of local polymer-based and systemic delivery of the anti-glutamatergic agents riluzole and memantine in rat glioma models. Journal of Neurosurgery, 2014, 120, 854-863.	1.6	21
72	Local delivery of angiogenesis-inhibitor minocycline combined with radiotherapy and oral temozolomide chemotherapy in 9L glioma. Journal of Neurosurgery, 2014, 120, 662-669.	1.6	29

BETTY M TYLER

#	Article	IF	CITATIONS
73	Radiosensitization of malignant gliomas following intracranial delivery of paclitaxel biodegradable polymer microspheres. Journal of Neurosurgery, 2014, 120, 1078-1085.	1.6	15
74	Quantitative multiparametric MRI assessment of glioma response to radiotherapy in a rat model. Neuro-Oncology, 2014, 16, 856-867.	1.2	45
75	Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model. Journal of Neuro-Oncology, 2013, 111, 229-236.	2.9	72
76	Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model. Cancer Chemotherapy and Pharmacology, 2013, 72, 93-100.	2.3	15
77	Increased expression of glutamate transporter GLT-1 in peritumoral tissue associated with prolonged survival and decreases in tumor growth in a rat model of experimental malignant glioma. Journal of Neurosurgery, 2013, 119, 878-886.	1.6	24
78	The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas. Cancer Chemotherapy and Pharmacology, 2012, 70, 129-139.	2.3	14
79	Intracranial MEMS based temozolomide delivery in a 9L rat gliosarcoma model. Biomaterials, 2012, 33, 5768-5775.	11.4	60
80	Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model. Biomaterials, 2011, 32, 2532-2539.	11.4	75
81	Delayed onset of paresis in rats with experimental intramedullary spinal cord gliosarcoma following intratumoral administration of the paclitaxel delivery system OncoGel. Journal of Neurosurgery: Spine, 2011, 16, 1-9.	1.7	17
82	Local delivery of rapamycin: a toxicity and efficacy study in an experimental malignant glioma model in rats. Neuro-Oncology, 2011, 13, 700-709.	1.2	28
83	Combination of Intracranial Temozolomide With Intracranial Carmustine Improves Survival When Compared With Either Treatment Alone in a Rodent Glioma Model. Neurosurgery, 2010, 66, 530-537.	1.1	57
84	A thermal gel depot for local delivery of paclitaxel to treat experimental brain tumors in rats. Journal of Neurosurgery, 2010, 113, 210-217.	1.6	76
85	Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opinion on Drug Safety, 2007, 6, 609-621.	2.4	388
86	Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank model. Journal of Controlled Release, 2007, 123, 172-178.	9.9	85
87	Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemotherapy and Pharmacology, 2007, 60, 643-650.	2.3	81
88	Local Delivery of a Synthetic Endostatin Fragment for the Treatment of Experimental Gliomas. Neurosurgery, 2005, 57, 1032-1040.	1.1	23
89	Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. Anticancer Research, 2005, 25, 3825-31.	1.1	100
90	Gene Therapy for Experimental Brain Tumors Using a Xenogenic Cell Line Engineered to Secrete hIL-2. Journal of Neuro-Oncology, 2003, 64, 155-160.	2.9	0

#	Article	IF	CITATIONS
91	Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma. Journal of Neuro-Oncology, 2003, 64, 203-209.	2.9	38
92	Camptothecin analogs in malignant gliomas: comparative analysis and characterization. Journal of Neurosurgery, 2003, 98, 570-577.	1.6	19
93	Polilactofate microspheres for Paclitaxel delivery to central nervous system malignancies. Clinical Cancer Research, 2003, 9, 3441-7.	7.0	50
94	Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats. Journal of Neurosurgery, 2002, 97, 1173-1178.	1.6	54
95	Polymer delivery of camptothecin against 9L gliosarcoma: release, distribution, and efficacy. Journal of Neuro-Oncology, 2002, 56, 209-217.	2.9	84
96	Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors. Pharmaceutical Research, 2001, 18, 899-906.	3.5	86
97	Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemotherapy and Pharmacology, 1997, 39, 383-389.	2.3	112
98	Effects of GLIADEL® wafer initial molecular weight on the erosion of wafer and release of BCNU. Journal of Controlled Release, 1996, 42, 83-92.	9.9	74
99	Chemotherapeutic drugs released from polymers: distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat brain. Pharmaceutical Research, 1996, 13, 671-682.	3.5	190
100	Interstitial delivery of carboplatin via biodegradable Polymers is effective against experimental glioma in the rat. Cancer Chemotherapy and Pharmacology, 1996, 39, 90-96.	2.3	94
101	Local delivery of the topoisomerase I inhibitor camptothecin sodium prolongs survival in the rat intracranial 9L gliosarcoma model. International Journal of Cancer, 1995, 62, 605-609.	5.1	62
102	Delayed onset of paresis in rats with experimental intramedullary spinal cord gliosarcoma following intratumoral administration of the paclitaxel delivery system OncoGel. Journal of Neurosurgery: Spine, 0, , 1-9.	1.7	0